Developer docs
API playgroundTry for free, no card

Search company profiles

Rubió

Full company profile

uuid0003539

Namestring
Rubió
Legal namestring
LABORATORIOS RUBIÓ, SA
Company typeenum
Private
Founded yearint
1968
Descriptiontext

Laboratorios Rubió is a privately-held Spanish pharmaceutical company founded in 1968 and headquartered in Castellbisbal, Barcelona. The company manufactures and commercializes licensed pharmaceutical products across multiple therapeutic areas — including ADHD (Rubifen, Rubifen Prolong, Rubicrono, Atamax), rheumatology and pain (Dolquine, Naprosyn, Antalgin), osteoporosis (Bonviva, Soludronate, Rocaltrol, Mastical D), nephrology (Fosquel, Resincalcio, Resincolestiramina), urology (Cystistat), andrology (Testogel), gynecology (Utrogestan), and adjuvant therapies — alongside nutritional supplements (the Profertil fertility range), medical devices (Gelsectan, Cicatridina, Suplasyn), and proprietary in vitro diagnostics (OWLiver for MASLD/MASH, Liposcale for advanced lipoprotein profiling). Manufacturing is centered on a 2,900 m² GMP-compliant plant exceeding 10 million finished units annually, with a multi-year expansion to nearly double capacity underway.

Rubió operates four business areas — Pharmaceuticals, OTC Nutraceuticals, Metabolomics, and Diagnostics — and earns revenue primarily through unit-pricing model sales of prescription and OTC products in Spain and through licensing and distribution arrangements with 80+ strategic partners across more than 70 countries. The pricing across the portfolio spans from budget generics (Rubifen 5mg at €2.42) to specialized treatments (Fosquel 2.4g at €194.70), with most products reimbursed through Spanish Social Security. Distribution outside Spain relies on partner-channel and licensing-out agreements, plus a dedicated U.S. joint venture (CIMA Sciences) for the OWLiver diagnostic. Vertically integrated capabilities include the in-house metabolomics platform (LC/MS and NMR) developed through the 2022 acquisition of Rubió Metabolomics / OWL Metabolomics, supporting both proprietary diagnostic products and third-party R&D services.

The customer base comprises healthcare professionals, hospitals, pharmacies, and patients across the 70+ countries served, with no single named customer or region dominating disclosed revenue. Recent strategic moves include acquisitions of Fisiopharma (2021), Rubió Metabolomics (2022), Rubió Nutraceuticals Italy (2023), and Nutribrain (2024), alongside the founding of the CIMA Sciences joint venture and an active Digital Health Startup Program targeting urology, rheumatology, CNS, nephrology, and gastroenterology startups. FY2024 revenue reached €181M (+38.23% YoY), with 284 employees across Spain and Italy and the first disclosed external financing (€4.65M from ICF) recorded in July 2025.

Short descriptiontext

Laboratorios Rubió is a private Spanish pharmaceutical company founded in 1968 that manufactures and distributes prescription medicines, nutraceuticals, medical devices, and proprietary diagnostic tests (OWLiver, Liposcale) through direct sales in Spain and 80+ partners across 70+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCastellbisbal, Spain
HQ citystring
Castellbisbal
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, in vitro diagnostics, nutraceutical supplements, metabolomics testing, specialty generic medicines
Industry3 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYAFAJAKAK
Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Services-Commercial Physical & Biological Research8731
Product category
Specialty Pharmaceuticals and In Vitro Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Products
TypeOne Time License
Description

Manufacturing and sales of established medicines with strong reputation, introducing new products annually through proprietary R&D and third-party alliances. Focus on therapeutic areas including Rheumatology, Nephrology, Urology, CNS, and others.

laboratoriosrubio.com
2Diagnostic Products
TypeOne Time License
Description

In vitro diagnostic tests including OWLiver for non-invasive liver disease diagnosis and Liposcale for advanced lipoprotein analysis for cardiovascular risk assessment.

laboratoriosrubio.com
3OTC Nutraceuticals
TypeOne Time License
Description

Complete formulas for food supplements targeting osteoarticular and muscular health, distributed through Fisiopharma and Rubió Nutraceuticals.

laboratoriosrubio.com
4Licensing and Distribution
TypeLicensing Royalties
Description

Commercialization and distribution agreements for third-party pharmaceutical products in Spain as local representative, including products from Atnahs Pharma, Besins Healthcare, and Lenus Pharma.

laboratoriosrubio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details5 tiers
1Rubifen (Methylphenidate) - Generic ADHD treatment
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Rubifen 5mg 30 tablets: €2.42; Rubifen 10mg 30 tablets: €4.84; Rubifen 20mg 30 tablets: €5.71 - All require medical prescription

laboratoriosrubio.com
2Rubifen Prolong (Extended-release Methylphenidate)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Rubifen Prolong 20mg 30 capsules: €11.94; 30mg: €17.91; 40mg: €23.88; 60mg: €35.83

laboratoriosrubio.com
3Naprosyn (Naproxen 500mg)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Naprosyn 500mg 40 tablets: €4.34 - Requires medical prescription

laboratoriosrubio.com
4Dolquine (Hydroxychloroquine)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Dolquine 200mg 30 tablets: €12.16; 60 tablets: €24.32; 300mg 30 tablets: €18.25 - Financed by Social Security with reduced co-payment

laboratoriosrubio.com
5Fosquel (Sevelamer Carbonate)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Fosquel 2.4g powder 90 sachets: €194.70; Fosquel 800mg 180 tablets: €145.71 - Financed by Social Security with reduced co-payment

laboratoriosrubio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Campus Rubió
Description

Educational and training platform of Laboratorios Rubió offering courses, conferences, and events for professional development.

laboratoriosrubio.com
+1 more record
Core offering1 text field

Laboratorios Rubió manufactures and commercializes specialty pharmaceutical products (notably methylphenidate-based ADHD treatments, hydroxychloroquine, naproxen, sevelamer, ibandronic acid, alendronic acid, testosterone, calcitriol), licensed nutritional supplements (Profertil fertility line, Fisiopharma osteoarticular range, Nutribrain cognitive health), medical devices (Gelsectan for IBS, Cicatridina, Suplasyn for joints, Actim diagnostics), and proprietary in vitro diagnostics (OWLiver for MASLD, Liposcale for lipoprotein profiling). Production runs at a GMP-certified Castellbisbal plant, with commercial reach through Spanish wholesalers and 80+ international strategic partners across 70+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 38.23% revenue growth in 2024, reaching €181 million
+2 more records
Product overview1 text field

Laboratorios Rubió is a Spanish pharmaceutical company with over 50 years of experience operating through four main business areas: Pharmaceuticals, OTC Nutraceuticals, Metabolomics, and Diagnostics. The company manufactures and commercializes a broad portfolio of licensed pharmaceutical products (including Rubifen®, Rubicrono®, Rubifen Prolong® for ADHD; Dolquine® for rheumatoid arthritis and malaria; Naprosyn®/Antalgin® for pain/inflammation; Bonviva®/Soludronate® for osteoporosis; Rocaltrol® for bone disorders; Testogel® for testosterone replacement; and kidney-related products like Fosquel®, Resincalcio®, Resincolestiramina®), licensed nutritional supplements (Profertil® family for fertility/reproductive health), licensed medical devices (Gelsectan® for IBS, Cicatridina® for wound healing, Suplasyn® for joints), and proprietary diagnostic products (OWLiver® for MASLD diagnosis via metabolomics, Liposcale® for advanced lipoprotein profiling). The company operates its own 2,900m² GMP-certified manufacturing plant in Castellbisbal, Barcelona with capacity exceeding 10 million finished units annually.

Product and service27 records
1Utrogestan
CategoryLicensed pharmaceutical product
Description

Vaginal soft capsules containing micronized progesterone, indicated for luteal phase supplementation during assisted reproduction techniques (ART) and prevention of preterm birth in women with short cervical length. Sold under license in Spain.

2Rubifen Prolong
CategoryLicensed pharmaceutical product
Description

Modified-release hard capsules containing methylphenidate (50% immediate release, 50% extended release), indicated for ADHD treatment in children from 6 years, adolescents, and adults.

3Rubifen
CategoryLicensed pharmaceutical product
Description

Tablets containing methylphenidate hydrochloride, indicated as part of a comprehensive ADHD treatment program in children from 6 years under specialist supervision.

4Rubicrono
CategoryLicensed pharmaceutical product
Description

Extended-release tablets containing methylphenidate hydrochloride, indicated as part of a comprehensive ADHD treatment program in children from 6 years.

5Atamax
CategoryLicensed pharmaceutical product
Description

Hard capsules containing atomoxetine hydrochloride, indicated for ADHD treatment in children from 6 years, adolescents, and adults as part of a complete treatment program.

6Naprosyn 500 mg
CategoryLicensed pharmaceutical product
Description

Tablets containing naproxen 500 mg, indicated for treatment of mild to moderate pain, symptomatic treatment of rheumatoid arthritis, osteoarthritis, acute gout episodes, ankylosing spondylitis, primary dysmenorrhea, acute migraine attacks, and menorrhagia.

7Antalgin
CategoryLicensed pharmaceutical product
Description

Film-coated tablets containing naproxen sodium 550 mg, indicated for mild to moderate pain, symptomatic treatment of rheumatoid arthritis, osteoarthritis, acute gout, dysmenorrhea, migraine attacks, and menorrhagia.

8Dolquine
CategoryLicensed pharmaceutical product
Description

Film-coated tablets containing hydroxychloroquine sulfate, indicated for treatment of acute or chronic rheumatoid arthritis, systemic and discoid lupus erythematosus, and prophylaxis and treatment of uncomplicated malaria.

9Bonviva 150 mg
CategoryLicensed pharmaceutical product
Description

Film-coated tablets containing ibandronic acid 150 mg, indicated for treatment of osteoporosis in postmenopausal women at high risk of fractures.

10Soludronate Weekly 70 mg
CategoryLicensed pharmaceutical product
Description

Oral solution containing alendronic acid 70 mg, indicated for treatment of postmenopausal osteoporosis, reducing the risk of vertebral and hip fractures.

11Fosquel
CategoryLicensed pharmaceutical product
Description

Tablets and oral powder for suspension containing sevelamer carbonate, indicated for control of hyperphosphatemia in adult patients on hemodialysis or peritoneal dialysis and in chronic kidney disease patients.

12Resincolestiramina
CategoryLicensed pharmaceutical product
Description

Oral powder for suspension containing calcium polystyrene sulfonate, indicated for treatment of hypercholesterolemia, pruritus associated with partial biliary obstruction, and bile acid malabsorption.

13Resincalcio
CategoryLicensed pharmaceutical product
Description

Oral powder for suspension containing calcium polystyrene sulfonate, indicated for treatment and prevention of hyperkalemia.

14Cystistat
CategoryLicensed pharmaceutical product
Description

Sterile solution of sodium hyaluronate for temporary replacement of the glycosaminoglycan (GAG) layer of the urinary bladder, indicated for radiation cystitis, infectious cystitis, interstitial cystitis, and hemorrhagic cystitis.

15Testogel 50 mg
CategoryLicensed pharmaceutical product
Description

Transdermal gel containing testosterone 50 mg per sachet, indicated for testosterone replacement therapy in adults with male hypogonadism.

16Rocaltrol
CategoryLicensed pharmaceutical product
Description

Soft capsules containing calcitriol (0.25 or 0.50 micrograms), indicated for renal osteodystrophy, post-surgical and idiopathic hypoparathyroidism, pseudo hypoparathyroidism, vitamin D-dependent rickets, and osteoporosis.

17Mastical D
CategoryLicensed pharmaceutical product
Description

Chewable tablets containing calcium and vitamin D3 in various dosages (500 mg/400 UI, 500 mg/800 UI, 500 mg/1000 UI), indicated for prevention and treatment of calcium and vitamin D deficiency in adults at associated risk.

18Profertil
CategoryLicensed nutritional supplement
Description

Nutritional supplement containing L-carnitine, L-arginine, coenzyme Q10, glutathione, vitamins and minerals, contributing to normal fertility function, reproduction, and spermatogenesis in men.

19Profertil female
CategoryLicensed nutritional supplement
Description

Nutritional supplement containing folic acid, selenium, vitamin E, coenzyme Q10, green tea extract catechins, licorice extract glycrrhizin, and omega-3 fatty acids, supporting women who want to conceive.

20Profertil Inositol
CategoryLicensed nutritional supplement
Description

Nutritional supplement containing myo-inositol, vitamin B6, folic acid (folate), and Quatrefolic, supporting physiological functions and homocysteine metabolism.

21OWLiver
CategoryIn-house diagnostic product
Description

Non-invasive serum-based metabolomic diagnostic test using lipidomic analysis via UHPLC-MS to diagnose and monitor MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) across all disease stages. CE-marked under Directive 98/79/EC.

22Liposcale
CategoryLicensed diagnostic product
Description

Advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy that comprehensively characterizes lipoprotein profiles including size, concentration, and lipid composition of VLDL, LDL, and HDL subclasses.

23Gelsectan
CategoryLicensed medical device
Description

Medical device containing xyloglucan for restoring intestinal function in patients with Irritable Bowel Syndrome (IBS) symptoms including chronic diarrhea, abdominal distension, pain, and flatulence.

24Cicatridina
CategoryLicensed medical device
Description

Medical device containing sodium hyaluronate for vaginal and anorectal healing, indicated for atrophic and dystrophic repair processes including postpartum recovery, gynecological surgeries, hemorrhoids, and anal fissures.

25Suplasyn
CategoryLicensed medical device
Description

Medical device containing sodium hyaluronate for joint supplementation.

26Actim Partus
CategoryLicensed medical device
Description

Diagnostic medical device for parturition detection.

27Actim Prom
CategoryLicensed medical device
Description

Diagnostic medical device for premature rupture of membranes detection.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Rubió Group (OWL Metabolomics)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-14
Description

Rubió Metabolomics joined the Rubió Group as a strategic alliance for advancing metabolomics and personalized medicine. This acquisition enhances capacity to develop diagnostic products and research services, leveraging synergies with Rubió Group's existing pharmaceutical expertise.

laboratoriosrubio.com
2CIMA Sciences
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture founded in 2022 in the United States for international commercialization of OWLiver, the leading non-invasive diagnostic test for MASLD/MASH. CIMA Sciences consolidates US market expansion and strengthens internationalization of OWLiver.

laboratoriosrubio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spin-off from Rovira i Virgili University (URV) and Pere Virgili Health Research Institute (IISPV), partially owned by Laboratorios Rubió. Specializes in development of in vitro diagnostic tests for cardiovascular risk evaluation in high-risk patients. Developed Liposcale technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration agreement with INCLIVA to promote biomedical research jointly.

Strategic tierMinorTypeOthers
Description

Collaboration with Cetacea for marine biodiversity preservation and sustainable future initiatives.

680+ International Strategic Partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Network of over 80 strategic partners managing commercial relationships and distribution agreements in more than 70 countries, focusing on key therapeutic areas, R&D, and health sector advancements.

laboratoriosrubio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spanish mid-cap pharmaceutical company with a similar multi-therapeutic portfolio (rheumatology, dermatology, OTC) and a recent track record of growth through acquisitions and international expansion, directly comparable in scale and geographic mix.

TypeDirect peer
Description

Spanish-listed pharmaceutical manufacturer of similar size with own manufacturing, specialty therapeutics, and a focus on international licensing; directly comparable business model of branded-generic specialty pharma with export-driven growth.

TypeBroad incumbent
Description

Spain's largest listed dermatology-focused pharma, but with broad specialty prescription products and a similar GMP manufacturing footprint; broader therapeutic reach but overlapping in established-molecule European distribution.

4Laboratorios Esteve
TypeDirect peer
Description

Family-controlled Spanish pharma with parallel portfolio spread across multiple therapeutic areas, generics and licensing activities, and a developing international and nutraceuticals footprint — closely analogous in scope and ownership structure.

5Casen Recordati
TypeRegional player
Description

Spanish subsidiary of Italian Recordati, focused on branded specialty pharma across urology, endocrinology, and gastroenterology — significant portfolio overlap with Rubió in Spain, particularly in urology/cystitis and gastroenterology.

TypeBroad incumbent
Description

Major European generics and specialty pharma group with broad therapeutic areas and a multi-country partner distribution model that closely mirrors Rubió's 80-partner, 70+ country positioning.

TypeDirect peer
Description

Slovenian generics and specialty pharma with own manufacturing, broad therapeutic spread, and export-led growth exceeding 90% of sales — virtually the same mid-cap European generics+specialty playbook as Rubió.

TypeBroad incumbent
Description

Italian mid-cap specialty pharma focused on rare diseases, urology, and gastroenterology; operates in adjacent therapeutic categories to Rubió and shares the Mediterranean European specialty pharma archetype.

TypeBroad incumbent
Description

Italian private/family-owned pharma with extensive branded prescription and OTC portfolio across Europe — comparable governance model (private/family), portfolio breadth, and Mediterranean European operating footprint.

TypeEmerging player
Description

Polish pharma with a broad generics/specialty portfolio and export focus — analogous mid-size European player with established-molecule focus and ongoing expansion beyond home market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rubió

Specialty Pharmaceuticals and In Vitro Diagnosticslaboratoriosrubio.com

Laboratorios Rubió is a private Spanish pharmaceutical company founded in 1968 that manufactures and distributes prescription medicines, nutraceuticals, medical devices, and proprietary diagnostic tests (OWLiver, Liposcale) through direct sales in Spain and 80+ partners across 70+ countries.

What Rubió does

Laboratorios Rubió is a privately-held Spanish pharmaceutical company founded in 1968 and headquartered in Castellbisbal, Barcelona. The company manufactures and commercializes licensed pharmaceutical products across multiple therapeutic areas — including ADHD (Rubifen, Rubifen Prolong, Rubicrono, Atamax), rheumatology and pain (Dolquine, Naprosyn, Antalgin), osteoporosis (Bonviva, Soludronate, Rocaltrol, Mastical D), nephrology (Fosquel, Resincalcio, Resincolestiramina), urology (Cystistat), andrology (Testogel), gynecology (Utrogestan), and adjuvant therapies — alongside nutritional supplements (the Profertil fertility range), medical devices (Gelsectan, Cicatridina, Suplasyn), and proprietary in vitro diagnostics (OWLiver for MASLD/MASH, Liposcale for advanced lipoprotein profiling). Manufacturing is centered on a 2,900 m² GMP-compliant plant exceeding 10 million finished units annually, with a multi-year expansion to nearly double capacity underway.

Rubió operates four business areas — Pharmaceuticals, OTC Nutraceuticals, Metabolomics, and Diagnostics — and earns revenue primarily through unit-pricing model sales of prescription and OTC products in Spain and through licensing and distribution arrangements with 80+ strategic partners across more than 70 countries. The pricing across the portfolio spans from budget generics (Rubifen 5mg at €2.42) to specialized treatments (Fosquel 2.4g at €194.70), with most products reimbursed through Spanish Social Security. Distribution outside Spain relies on partner-channel and licensing-out agreements, plus a dedicated U.S. joint venture (CIMA Sciences) for the OWLiver diagnostic. Vertically integrated capabilities include the in-house metabolomics platform (LC/MS and NMR) developed through the 2022 acquisition of Rubió Metabolomics / OWL Metabolomics, supporting both proprietary diagnostic products and third-party R&D services.

The customer base comprises healthcare professionals, hospitals, pharmacies, and patients across the 70+ countries served, with no single named customer or region dominating disclosed revenue. Recent strategic moves include acquisitions of Fisiopharma (2021), Rubió Metabolomics (2022), Rubió Nutraceuticals Italy (2023), and Nutribrain (2024), alongside the founding of the CIMA Sciences joint venture and an active Digital Health Startup Program targeting urology, rheumatology, CNS, nephrology, and gastroenterology startups. FY2024 revenue reached €181M (+38.23% YoY), with 284 employees across Spain and Italy and the first disclosed external financing (€4.65M from ICF) recorded in July 2025.

Rubió firmographics

Firmographics
Name
Rubió
Legal name
LABORATORIOS RUBIÓ, SA
Website
https://laboratoriosrubio.com
Company type
Private
Founded year
1968
Operating status
Operating
Headcount range
101–250 employees
Short description
Laboratorios Rubió is a private Spanish pharmaceutical company founded in 1968 that manufactures and distributes prescription medicines, nutraceuticals, medical devices, and proprietary diagnostic tests (OWLiver, Liposcale) through direct sales in Spain and 80+ partners across 70+ countries.
Ownership category
akta.pro rank

Rubió industry classification

Industry
Product category
Specialty Pharmaceuticals and In Vitro Diagnostics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYAFAJAKAK
Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Pharmaceutical manufacturing
  • In vitro diagnostics
  • Nutraceutical supplements
  • Metabolomics testing
  • Specialty generic medicines

Where Rubió is headquartered

Location

Headquarters

HQ city
Castellbisbal
HQ country
Spain
HQ region
Europe

Offices3 records

Markets served

Rubió business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Products: Manufacturing and sales of established medicines with strong reputation, introducing new products annually through proprietary R&D and third-party alliances. Focus on therapeutic areas including Rheumatology, Nephrology, Urology, CNS, and others.
  2. Diagnostic Products: In vitro diagnostic tests including OWLiver for non-invasive liver disease diagnosis and Liposcale for advanced lipoprotein analysis for cardiovascular risk assessment.
  3. OTC Nutraceuticals: Complete formulas for food supplements targeting osteoarticular and muscular health, distributed through Fisiopharma and Rubió Nutraceuticals.
  4. Licensing and Distribution: Commercialization and distribution agreements for third-party pharmaceutical products in Spain as local representative, including products from Atnahs Pharma, Besins Healthcare, and Lenus Pharma.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRubifen (Methylphenidate) - Generic ADHD treatment
Unit PricingPay-as-you-goRubifen Prolong (Extended-release Methylphenidate)
Unit PricingPay-as-you-goNaprosyn (Naproxen 500mg)
Unit PricingPay-as-you-goDolquine (Hydroxychloroquine)
Unit PricingPay-as-you-goFosquel (Sevelamer Carbonate)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Rubió product offering

Product offering

Core offering

Laboratorios Rubió manufactures and commercializes specialty pharmaceutical products (notably methylphenidate-based ADHD treatments, hydroxychloroquine, naproxen, sevelamer, ibandronic acid, alendronic acid, testosterone, calcitriol), licensed nutritional supplements (Profertil fertility line, Fisiopharma osteoarticular range, Nutribrain cognitive health), medical devices (Gelsectan for IBS, Cicatridina, Suplasyn for joints, Actim diagnostics), and proprietary in vitro diagnostics (OWLiver for MASLD, Liposcale for lipoprotein profiling). Production runs at a GMP-certified Castellbisbal plant, with commercial reach through Spanish wholesalers and 80+ international strategic partners across 70+ countries.

Product overview

Laboratorios Rubió is a Spanish pharmaceutical company with over 50 years of experience operating through four main business areas: Pharmaceuticals, OTC Nutraceuticals, Metabolomics, and Diagnostics. The company manufactures and commercializes a broad portfolio of licensed pharmaceutical products (including Rubifen®, Rubicrono®, Rubifen Prolong® for ADHD; Dolquine® for rheumatoid arthritis and malaria; Naprosyn®/Antalgin® for pain/inflammation; Bonviva®/Soludronate® for osteoporosis; Rocaltrol® for bone disorders; Testogel® for testosterone replacement; and kidney-related products like Fosquel®, Resincalcio®, Resincolestiramina®), licensed nutritional supplements (Profertil® family for fertility/reproductive health), licensed medical devices (Gelsectan® for IBS, Cicatridina® for wound healing, Suplasyn® for joints), and proprietary diagnostic products (OWLiver® for MASLD diagnosis via metabolomics, Liposcale® for advanced lipoprotein profiling). The company operates its own 2,900m² GMP-certified manufacturing plant in Castellbisbal, Barcelona with capacity exceeding 10 million finished units annually.

Differentiator

Problem solved

Functional benefit

Brands

  • Campus Rubió: Educational and training platform of Laboratorios Rubió offering courses, conferences, and events for professional development.
  • Digital Health Startup Program

Products and services

  • Utrogestan Vaginal soft capsules containing micronized progesterone, indicated for luteal phase supplementation during assisted reproduction techniques (ART) and prevention of preterm birth in women with short cervical length. Sold under license in Spain.
  • Rubifen Prolong Modified-release hard capsules containing methylphenidate (50% immediate release, 50% extended release), indicated for ADHD treatment in children from 6 years, adolescents, and adults.
  • Rubifen Tablets containing methylphenidate hydrochloride, indicated as part of a comprehensive ADHD treatment program in children from 6 years under specialist supervision.
  • Rubicrono Extended-release tablets containing methylphenidate hydrochloride, indicated as part of a comprehensive ADHD treatment program in children from 6 years.
  • Atamax Hard capsules containing atomoxetine hydrochloride, indicated for ADHD treatment in children from 6 years, adolescents, and adults as part of a complete treatment program.
  • Naprosyn 500 mg Tablets containing naproxen 500 mg, indicated for treatment of mild to moderate pain, symptomatic treatment of rheumatoid arthritis, osteoarthritis, acute gout episodes, ankylosing spondylitis, primary dysmenorrhea, acute migraine attacks, and menorrhagia.
  • Antalgin Film-coated tablets containing naproxen sodium 550 mg, indicated for mild to moderate pain, symptomatic treatment of rheumatoid arthritis, osteoarthritis, acute gout, dysmenorrhea, migraine attacks, and menorrhagia.
  • Dolquine Film-coated tablets containing hydroxychloroquine sulfate, indicated for treatment of acute or chronic rheumatoid arthritis, systemic and discoid lupus erythematosus, and prophylaxis and treatment of uncomplicated malaria.
  • Bonviva 150 mg Film-coated tablets containing ibandronic acid 150 mg, indicated for treatment of osteoporosis in postmenopausal women at high risk of fractures.
  • Soludronate Weekly 70 mg Oral solution containing alendronic acid 70 mg, indicated for treatment of postmenopausal osteoporosis, reducing the risk of vertebral and hip fractures.
  • Fosquel Tablets and oral powder for suspension containing sevelamer carbonate, indicated for control of hyperphosphatemia in adult patients on hemodialysis or peritoneal dialysis and in chronic kidney disease patients.
  • Resincolestiramina Oral powder for suspension containing calcium polystyrene sulfonate, indicated for treatment of hypercholesterolemia, pruritus associated with partial biliary obstruction, and bile acid malabsorption.
  • Resincalcio Oral powder for suspension containing calcium polystyrene sulfonate, indicated for treatment and prevention of hyperkalemia.
  • Cystistat Sterile solution of sodium hyaluronate for temporary replacement of the glycosaminoglycan (GAG) layer of the urinary bladder, indicated for radiation cystitis, infectious cystitis, interstitial cystitis, and hemorrhagic cystitis.
  • Testogel 50 mg Transdermal gel containing testosterone 50 mg per sachet, indicated for testosterone replacement therapy in adults with male hypogonadism.
  • Rocaltrol Soft capsules containing calcitriol (0.25 or 0.50 micrograms), indicated for renal osteodystrophy, post-surgical and idiopathic hypoparathyroidism, pseudo hypoparathyroidism, vitamin D-dependent rickets, and osteoporosis.
  • Mastical D Chewable tablets containing calcium and vitamin D3 in various dosages (500 mg/400 UI, 500 mg/800 UI, 500 mg/1000 UI), indicated for prevention and treatment of calcium and vitamin D deficiency in adults at associated risk.
  • Profertil Nutritional supplement containing L-carnitine, L-arginine, coenzyme Q10, glutathione, vitamins and minerals, contributing to normal fertility function, reproduction, and spermatogenesis in men.
  • Profertil female Nutritional supplement containing folic acid, selenium, vitamin E, coenzyme Q10, green tea extract catechins, licorice extract glycrrhizin, and omega-3 fatty acids, supporting women who want to conceive.
  • Profertil Inositol Nutritional supplement containing myo-inositol, vitamin B6, folic acid (folate), and Quatrefolic, supporting physiological functions and homocysteine metabolism.
  • OWLiver Non-invasive serum-based metabolomic diagnostic test using lipidomic analysis via UHPLC-MS to diagnose and monitor MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) across all disease stages. CE-marked under Directive 98/79/EC.
  • Liposcale Advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy that comprehensively characterizes lipoprotein profiles including size, concentration, and lipid composition of VLDL, LDL, and HDL subclasses.
  • Gelsectan Medical device containing xyloglucan for restoring intestinal function in patients with Irritable Bowel Syndrome (IBS) symptoms including chronic diarrhea, abdominal distension, pain, and flatulence.
  • Cicatridina Medical device containing sodium hyaluronate for vaginal and anorectal healing, indicated for atrophic and dystrophic repair processes including postpartum recovery, gynecological surgeries, hemorrhoids, and anal fissures.
  • Suplasyn Medical device containing sodium hyaluronate for joint supplementation.
  • Actim Partus Diagnostic medical device for parturition detection.
  • Actim Prom Diagnostic medical device for premature rupture of membranes detection.

Quantifiable outcome

  • 38.23% revenue growth in 2024, reaching €181 million
  • +2 more outcomes

Companies that use Rubió

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Rubió technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Rubió partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Rubió Group (OWL Metabolomics)coreStrategic or Co-development Partner · 14 June 2023Rubió Metabolomics joined the Rubió Group as a strategic alliance for advancing metabolomics and personalized medicine. This acquisition enhances capacity to develop diagnostic products and research services, leveraging synergies with Rubió Group's existing pharmaceutical expertise.
  • CIMA SciencescoreStrategic or Co-development PartnerJoint venture founded in 2022 in the United States for international commercialization of OWLiver, the leading non-invasive diagnostic test for MASLD/MASH. CIMA Sciences consolidates US market expansion and strengthens internationalization of OWLiver.
  • Biosfer TeslabcoreStrategic or Co-development PartnerSpin-off from Rovira i Virgili University (URV) and Pere Virgili Health Research Institute (IISPV), partially owned by Laboratorios Rubió. Specializes in development of in vitro diagnostic tests for cardiovascular risk evaluation in high-risk patients. Developed Liposcale technology.
  • INCLIVAminorStrategic or Co-development PartnerCollaboration agreement with INCLIVA to promote biomedical research jointly.
  • CetaceaminorOthersCollaboration with Cetacea for marine biodiversity preservation and sustainable future initiatives.
  • 80+ International Strategic PartnerscoreChannel Partner/ Reseller/ DistributorNetwork of over 80 strategic partners managing commercial relationships and distribution agreements in more than 70 countries, focusing on key therapeutic areas, R&D, and health sector advancements.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Rubió competitors and assessment

Company assessment

Direct peers

  • Faes Farma: Spanish mid-cap pharmaceutical company with a similar multi-therapeutic portfolio (rheumatology, dermatology, OTC) and a recent track record of growth through acquisitions and international expansion, directly comparable in scale and geographic mix.
  • Laboratorios Farmaceuticos Rovi (ROVI): Spanish-listed pharmaceutical manufacturer of similar size with own manufacturing, specialty therapeutics, and a focus on international licensing; directly comparable business model of branded-generic specialty pharma with export-driven growth.
  • Laboratorios Esteve: Family-controlled Spanish pharma with parallel portfolio spread across multiple therapeutic areas, generics and licensing activities, and a developing international and nutraceuticals footprint — closely analogous in scope and ownership structure.
  • KRKA: Slovenian generics and specialty pharma with own manufacturing, broad therapeutic spread, and export-led growth exceeding 90% of sales — virtually the same mid-cap European generics+specialty playbook as Rubió.

Broad incumbents

  • Almirall: Spain's largest listed dermatology-focused pharma, but with broad specialty prescription products and a similar GMP manufacturing footprint; broader therapeutic reach but overlapping in established-molecule European distribution.
  • Stada Arzneimittel: Major European generics and specialty pharma group with broad therapeutic areas and a multi-country partner distribution model that closely mirrors Rubió's 80-partner, 70+ country positioning.
  • Recordati: Italian mid-cap specialty pharma focused on rare diseases, urology, and gastroenterology; operates in adjacent therapeutic categories to Rubió and shares the Mediterranean European specialty pharma archetype.
  • Menarini Group: Italian private/family-owned pharma with extensive branded prescription and OTC portfolio across Europe — comparable governance model (private/family), portfolio breadth, and Mediterranean European operating footprint.

Regional players

  • Casen Recordati: Spanish subsidiary of Italian Recordati, focused on branded specialty pharma across urology, endocrinology, and gastroenterology — significant portfolio overlap with Rubió in Spain, particularly in urology/cystitis and gastroenterology.

Emerging players

  • Polpharma: Polish pharma with a broad generics/specialty portfolio and export focus — analogous mid-size European player with established-molecule focus and ongoing expansion beyond home market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Rubió social profiles

Digital presence

Rubió financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rubió leadership team

Management profile

Number of profiles

Profiles5 records

Rubió subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Rubió funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rubió M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rubió

What does Rubió do?

Laboratorios Rubió manufactures and commercializes specialty pharmaceutical products (notably methylphenidate-based ADHD treatments, hydroxychloroquine, naproxen, sevelamer, ibandronic acid, alendronic acid, testosterone, calcitriol), licensed nutritional supplements (Profertil fertility line, Fisiopharma osteoarticular range, Nutribrain cognitive health), medical devices (Gelsectan for IBS, Cicatridina, Suplasyn for joints, Actim diagnostics), and proprietary in vitro diagnostics (OWLiver for MASLD, Liposcale for lipoprotein profiling). Production runs at a GMP-certified Castellbisbal plant, with commercial reach through Spanish wholesalers and 80+ international strategic partners across 70+ countries.

Is Rubió a public or private company?

Rubió is a private company. It is classified as family owned and is currently operating.

When was Rubió founded?

Rubió was founded in 1968. It employs 101 to 250 people.

Where is Rubió based?

Rubió is headquartered in Castellbisbal, Spain, in the Europe region.

How does Rubió make money?

Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are diagnostic Products, OTC Nutraceuticals and licensing and Distribution.

Who are Rubió's main competitors?

Direct peers on record are Faes Farma, Laboratorios Farmaceuticos Rovi (ROVI), Laboratorios Esteve and KRKA. Broad incumbents are Almirall, Stada Arzneimittel, Recordati and Menarini Group. Casen Recordati is listed as a regional player. Polpharma is listed as an emerging player.

Does Rubió have an API?

No public API is recorded for Rubió.

What industry is Rubió in?

Rubió's product category is Specialty Pharmaceuticals and In Vitro Diagnostics. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals